These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

254 related articles for article (PubMed ID: 32197462)

  • 1. A Spanish Consensus on the Use of Safinamide for Parkinson's Disease in Clinical Practice.
    Pagonabarraga J; Arbelo JM; Grandas F; Luquin MR; Martínez Martín P; Rodríguez-Oroz MC; Valldeoriola F; Kulisevsky J
    Brain Sci; 2020 Mar; 10(3):. PubMed ID: 32197462
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Collective Expert Perspectives on the Use of Safinamide as Adjunctive Therapy for Parkinson's Disease: Online-Based Delphi Survey.
    Takeda A; Tsuboi Y; Nomoto M; Mochizuki H; Hattori N
    Parkinsons Dis; 2022; 2022():3203212. PubMed ID: 35873701
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Safinamide in the treatment pathway of Parkinson's Disease: a European Delphi Consensus.
    Stocchi F; Antonini A; Berg D; Bergmans B; Jost W; Katzenschlager R; Kulisevsky J; Odin P; Valldeoriola F; Ray Chaudhuri K
    NPJ Parkinsons Dis; 2022 Feb; 8(1):17. PubMed ID: 35190544
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Two-year, randomized, controlled study of safinamide as add-on to levodopa in mid to late Parkinson's disease.
    Borgohain R; Szasz J; Stanzione P; Meshram C; Bhatt MH; Chirilineau D; Stocchi F; Lucini V; Giuliani R; Forrest E; Rice P; Anand R;
    Mov Disord; 2014 Sep; 29(10):1273-80. PubMed ID: 25044402
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Assessment of Safety and Efficacy of Safinamide as a Levodopa Adjunct in Patients With Parkinson Disease and Motor Fluctuations: A Randomized Clinical Trial.
    Schapira AH; Fox SH; Hauser RA; Jankovic J; Jost WH; Kenney C; Kulisevsky J; Pahwa R; Poewe W; Anand R
    JAMA Neurol; 2017 Feb; 74(2):216-224. PubMed ID: 27942720
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The XINDI Study: A Randomized Phase III Clinical Trial Evaluating the Efficacy and Safety of Safinamide as Add-On Therapy to Levodopa in Chinese Patients with Parkinson's Disease with Motor Fluctuations.
    Wei Q; Tan Y; Xu P; Tao E; Lu Z; Pan X; Wang B; Liu C; Dong X; Tian Y; Sun X; Cattaneo C; Chen S; Shang H;
    CNS Drugs; 2022 Nov; 36(11):1217-1227. PubMed ID: 36346534
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Safinamide as Add-On Therapy to Levodopa in Mid- to Late-Stage Parkinson's Disease Fluctuating Patients: Post hoc Analyses of Studies 016 and SETTLE.
    Cattaneo C; Sardina M; Bonizzoni E
    J Parkinsons Dis; 2016; 6(1):165-73. PubMed ID: 26889632
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Efficacy of safinamide as add-on therapy after subthalamic nucleus deep brain stimulation in Parkinson disease.
    Rizzone MG; Mancini F; Artusi CA; Balestrino R; Bonvegna S; Fabbri M; Imbalzano G; Montanaro E; Romagnolo A; Zibetti M; Lopiano L
    Neurol Sci; 2022 May; 43(5):3187-3193. PubMed ID: 34982297
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Long-Term Efficacy of Safinamide on Symptoms Severity and Quality of Life in Fluctuating Parkinson's Disease Patients.
    Cattaneo C; Jost WH; Bonizzoni E
    J Parkinsons Dis; 2020; 10(1):89-97. PubMed ID: 31594253
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Safinamide in the management of patients with Parkinson's disease not stabilized on levodopa: a review of the current clinical evidence.
    Bette S; Shpiner DS; Singer C; Moore H
    Ther Clin Risk Manag; 2018; 14():1737-1745. PubMed ID: 30271159
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Randomized trial of safinamide add-on to levodopa in Parkinson's disease with motor fluctuations.
    Borgohain R; Szasz J; Stanzione P; Meshram C; Bhatt M; Chirilineau D; Stocchi F; Lucini V; Giuliani R; Forrest E; Rice P; Anand R;
    Mov Disord; 2014 Feb; 29(2):229-37. PubMed ID: 24323641
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Spanish expert consensus on the use of safinamide in Parkinson's disease.
    Valldeoriola F; Grandas F; Arbelo JM; Blázquez Estrada M; Calopa Garriga M; Campos-Arillo VM; Garcia Ruiz PJ; Gómez Esteban JC; Leiva Santana C; Martínez Castrillo JC; Mir P; Salvador Aliaga A; Vivancos Matellano F; Yáñez Baña RM
    Neurologia (Engl Ed); 2018 Jul; ():. PubMed ID: 30072274
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Spanish expert consensus on the use of safinamide in Parkinson's disease.
    Valldeoriola F; Grandas F; Arbelo JM; Blázquez Estrada M; Calopa Garriga M; Campos-Arillo VM; Garcia Ruiz PJ; Gómez Esteban JC; Leiva Santana C; Martínez Castrillo JC; Mir P; Salvador Aliaga A; Vivancos Matellano F; Yáñez Baña RM
    Neurologia (Engl Ed); 2021; 36(9):666-672. PubMed ID: 34752344
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Efficacy and safety of safinamide as an add-on therapy to L-DOPA for patients with Parkinson's disease: A randomized, double-blind, placebo-controlled, phase II/III study.
    Hattori N; Tsuboi Y; Yamamoto A; Sasagawa Y; Nomoto M;
    Parkinsonism Relat Disord; 2020 Jun; 75():17-23. PubMed ID: 32446176
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A systematic review and meta-analysis of safety and efficacy of safinamide for motor fluctuations in patients with Parkinson's disease.
    Abdelalem Aziz Ahmed M
    F1000Res; 2019; 8():2078. PubMed ID: 32431802
    [No Abstract]   [Full Text] [Related]  

  • 16. The Effects of Safinamide in Chinese and Non-Chinese Patients with Parkinson's Disease.
    Cattaneo C; Kulisevsky J
    Adv Ther; 2024 Feb; 41(2):638-648. PubMed ID: 38070039
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Switching from Rasagiline to Safinamide as an Add-On Therapy Regimen in Patients with Levodopa: A Literature Review.
    Sanchez Alonso P; De La Casa-Fages B; Alonso-Cánovas A; Martínez-Castrillo JC
    Brain Sci; 2023 Feb; 13(2):. PubMed ID: 36831820
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Long-Term Effects of Safinamide on Dyskinesia in Mid- to Late-Stage Parkinson's Disease: A Post-Hoc Analysis.
    Cattaneo C; Ferla RL; Bonizzoni E; Sardina M
    J Parkinsons Dis; 2015; 5(3):475-81. PubMed ID: 26406127
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Efficacy and safety evaluation of safinamide as an add-on treatment to levodopa for parkinson's disease.
    Kurihara K; Mishima T; Fujioka S; Tsuboi Y
    Expert Opin Drug Saf; 2022 Feb; 21(2):137-147. PubMed ID: 34597253
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Real life evaluation of safinamide effectiveness in Parkinson's disease.
    Mancini F; Di Fonzo A; Lazzeri G; Borellini L; Silani V; Lacerenza M; Comi C
    Neurol Sci; 2018 Apr; 39(4):733-739. PubMed ID: 29441484
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.